Inclusion Criteria:

          -  Written informed consent in accordance with federal, local, and institutional
             guidelines

          -  Patients with metastatic pancreatic adenocarcinoma not treated with chemotherapy for
             metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Absolute neutrophil count (ANC) >= 1500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Bilirubin < 2 times the upper limit of normal (ULN) (except patients with Gilbert's
             syndrome who must have a total bilirubin of < 3 times ULN)

          -  Alanine aminotransferase (ALT) < 2.5 times ULN

          -  Serum creatinine =< 1.5 mg/dL

          -  Serum albumin >= 3.0 g/dL

          -  Female patients of child-bearing potential must agree to use dual methods of
             contraception and have a negative serum pregnancy test at screening, and male patients
             must use an effective barrier method of contraception if sexually active with a female
             of child-bearing potential; acceptable methods of contraception are condoms with
             contraceptive foam, oral, implantable or injectable contraceptives, contraceptive
             patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is
             surgically sterilized or post-menopausal; for both male and female patients, effective
             methods of contraception must be used throughout the study and for three months
             following the last dose

          -  Patients with history of previously treated malignancies who have no evidence of
             disease for last five years are allowed to participate

        Exclusion Criteria:

          -  Patients who are pregnant or lactating

          -  Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 3 weeks
             prior to cycle 1 day 1; mitomycin C or radio-immunotherapy 6 weeks prior to cycle 1
             day 1

          -  Major surgery within four weeks before cycle 1 day 1

          -  Unstable cardiovascular function:

               -  Symptomatic ischemia, or

               -  Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular
                  tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular [AV]
                  block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch
                  block [RBBB] will not be excluded), or

               -  Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= 3,
                  or

               -  Myocardial infarction (MI) within 3 months of cycle 1 day 1 dose

          -  Uncontrolled active infection requiring parenteral antibiotics, antivirals, or
             antifungals within one week prior to first dose

          -  Known to be HIV seropositive who are on anti-HIV drugs because of the unknown
             interactions between these drugs and the study agents

          -  Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C
             virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus [HBV] surface antigen)

          -  Patients with active central nervous system (CNS) malignancy; asymptomatic small
             lesions are not considered active; treated lesions may be considered inactive if they
             are stable for at least 3 months

          -  Patients with significantly diseased or obstructed gastrointestinal tract or
             uncontrolled vomiting or diarrhea

          -  Grade >= 2 peripheral neuropathy within 14 days prior to cycle 1 day 1

          -  History of seizures, movement disorders or cerebrovascular accident within the past 5
             years prior to cycle 1 day 1

          -  Patients with muscular degeneration, uncontrolled glaucoma, or markedly decreased
             visual acuity based on physician's assessment

          -  Serious psychiatric or medical conditions that could interfere with treatment

          -  Participation in an investigational anti-cancer study within 3 weeks prior to cycle 1
             day 1

          -  Concurrent therapy with approved or investigational anticancer therapeutic

          -  Presence of clinically significant ascites